1887

Journal of General Virology header logo

Volume 78, Issue 9

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera Free

Abstract

A type-specific and neutralizing mouse MAb (V5) against human papillomavirus (HPV) type 16 capsids was found to block the serological reactivity of human sera with the corresponding capsids. Out of 352 human serum samples tested for the presence of IgG against HPV-16, more than 75% of reactive sera were completely blocked by the V5 antibody. Type-specific MAbs against HPV-6, −18 and −33 were also found to block serological reactivity with capsids of the corresponding HPV types for the majority of reactive human sera. The results suggest that most antibodies in human sera that are reactive with intact HPV capsids recognize the same or closely related major antigenic determinant(s).

  • Published Online:
© Society for General Microbiology 1997
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-9-2209
1997-09-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/9/9292008.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-9-2209&mimeType=html&fmt=ahah

References

  1. Andersson-Ellström A., Dillner J., Hagmar B., Schiller J., Sapp M., Forssman L., Milsom I. 1996a; Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sexually Transmitted Diseases 23:234–238
     [Google Scholar]
  2. Andersson-Ellström A., Hagmar B., Johansson B., Kalantari M., Wärleby B., Forssman L. 1996b; Human papillomavirus DNA in cervix only detected in girls after coitus. International Journal of STD & AIDS 23:234–238
     [Google Scholar]
  3. Breitburd F., Kirnbauer R., Hubbert N. L., Schiller J. T., Orth G. 1995; Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology 69:3959–3963
     [Google Scholar]
  4. Cheng G., Icenogle J. P., Kirnbauer R., Hubbert N. L., St Louis M. E., Han C., Svare E. I., Lowy D. R., Schiller J. T. 1995; Divergent human papillomavirus type 16 variants are serologically cross-reactive. Journal of Infectious Diseases 172:1584–1587
     [Google Scholar]
  5. Christensen N. D., Kreider J. W., Shah K. V., Rando R. F. 1992; Detection of human serum antibodies that neutralize infectious human papillomavirustype 11 virions. Journal of General Virology 73:1261–1267
     [Google Scholar]
  6. Christensen N. D., Cladel N. M., Reed C. A. 1995; Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 207:136–142
     [Google Scholar]
  7. Christensen N. D., Dillner J., Eklund C., Carter J. J., Reed C. A., Cladel N. M., Galloway D. A. 1996; Surface conformational and linear epitopes on HPV16 and HPV18 virus-like particles as defined by monoclonal antibodies. Virology 223:174–184
     [Google Scholar]
  8. Chua K., Wiklund F., Lenner P., Ångström T., Hallmans G., Bergman F., Sapp M., Schiller J., Wadell G., Hjerpe A., Dillner J. 1996; A prospective cohort study on the risk to develop cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV, in comparison with presence of HPV DNA in cervical smears. International Journal of Cancer 68:54–59
     [Google Scholar]
  9. Dillner J., Knekt P., Schiller J. T., Hakulinen T. 1995a; Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. British Medical Journal 311:1346
     [Google Scholar]
  10. Dillner J., Wiklund F., Lenner P., Eklund C., Fredriksson-Shanazarian V., Schiller J. T., Hibma M., Hallmans G., Stendahl U. 1995b; Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with cervical cancer. International Journal of Cancer 60:377–382
     [Google Scholar]
  11. Dillner L., Zellbi A., Åvall-Lundkvist E., Heino P., Pettersson C. A., Hansson B. G., Forslund O., Grandien M., Bistoletti P., Dillner J. 1995c; Association of serum antibodies against defined epitopes of human papillomavirus L1, E2 and E7 antigens and of HPV DNA with incident cervical cancer. Cancer Detection & Prevention 19:381–393
     [Google Scholar]
  12. Dillner J., Kallings I., Brihmer C., Sikström B., Koskela P., Lehtinen M., Schiller J. T., Sapp M., Mårdh P. A. 1996; Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. Journal of Infectious Diseases 173:1394–1398
     [Google Scholar]
  13. Friguet B., Chaffotte A. F., Djavadi-Ohaniance L., Goldberg M. E. 1985; Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. Journal of Immunological Methods 77:305–319
     [Google Scholar]
  14. Heino P., Skyldberg B., Lehtinen M., Rantala I., Hagmar B., Kreider J. W., Kirnbauer R., Dillner J. 1995; Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. Journal of General Virology 76:1142–1153
     [Google Scholar]
  15. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D. R., Schiller J. T. 1994; A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16. Journal of the National Cancer Institute 86:494–499
     [Google Scholar]
  16. Lehtinen M., Dillner J., Knekt P., Luostarinen T., Aromaa A., Kirnbauer R., Koskela P., Paavonen J., Peto R., Schiller J. T., Hakama M. 1996; Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma. British Medical Journal 312:537–539
     [Google Scholar]
  17. Roden R., Armstrong A., Haderer P., Christensen N., Hubbert N., Douglas R., Schiller J., Kirnbauer R. 1997; Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. Journal of Virology in press
    [Google Scholar]
  18. Schiffman M. H., Bauer H. M., Hoover R. N., Glass A. G., Cadell D. M., Rush B. B., Scott P. R., Sherman M. E., Kurman R. J., Wacholder S., Stanton C. K., Manos M. M. 1993; Epidemiological evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. Journal of the National Cancer Institute 85:958–964
     [Google Scholar]
  19. Schiller J. T., Okun M. M. 1996; Papillomavirus vaccines: current status and future source. Advances in Dermatology 11:355–380
     [Google Scholar]
  20. Schiller J. T., Roden R. B. S. 1995; Papillomavirus-like particles. Papillomavirus Report 6:121–128
     [Google Scholar]
  21. Strickler H. D., Schiffman M. H., Eklund C., Glass A. G., Lörincz A. T., Scott D. R., Sherman M. E., Kurman R. J., Manos M., Schiller J., Dillner J. 1997; Characterization of HPV antibody responses to squamous intraepithelial lesions of the cervix. Cancer Epidemiology, Biomarkers & Prevention 6:183–188
     [Google Scholar]
  22. Wideroff L., Schiffman M. H., Nonenmacher B., Hubbert N. K. R., Greer C. E., Lowy D., Lorincz A. T., Manos M. M., Glass A. G., Scott D. R., Sherman M. E., Kurman R. T., Buckland J., Tarone R. E., Schiller J. 1995; Evaluation of seroreactivity to HPV16 virus like- particles in an incident case-control study of cervical neoplasia. Journal of Infectious Diseases 172:1425–1430
     [Google Scholar]
  23. Wikström A., Van Doornum G. J. J., Quint W. G. V., Schiller J. T., Dillner J. 1995; Identification of human papillomavirus sero-conversions. Journal of General Virology 76:529–539
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-9-2209
Loading
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera
J. Gen. Virol. 78, 2209 (1997); https://doi.org/10.1099/0022-1317-78-9-2209
/content/journal/jgv/10.1099/0022-1317-78-9-2209
/content/journal/jgv/10.1099/0022-1317-78-9-2209
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error